Research Progress in mRNA Cancer Vaccines: Immunogenicity Regulation, Optimization of Lipid Nanoparticle Delivery Systems, and Challenges in Non-Hepatic Targeting

Open Access

Issue		BIO Web Conf. Volume 237, 2026 2026 8^th International Conference on Biotechnology and Biomedicine (ICBB 2026)


Article Number		02007
Number of page(s)		15
Section		Pharmacology, Natural Products and Drug Delivery
DOI		https://doi.org/10.1051/bioconf/202623702007
Published online		10 June 2026

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi:10.3322/caac.21834 [CrossRef] [PubMed] [Google Scholar]
Wathoni N, Puluhulawa LE, Joni IM, et al. Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer. Drug Deliv. 2022;29(1):2959–2970. doi:10.1080/10717544.2022.2120566 [Google Scholar]
Duan LJ, Wang Q, Zhang C, Yang DX, Zhang XY. Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy. Front Immunol. 2022;13:923647. Published 2022 May 26. doi:10.3389/fimmu.2022.923647 [Google Scholar]
Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41. Published 2021 Feb 25. doi:10.1186/s12943-021-01335-5 [Google Scholar]
Zong Y, Lin Y, Wei T, Cheng Q. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy. Adv Mater. 2023;35(51):e2303261. doi:10.1002/adma.202303261 [Google Scholar]
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279. doi:10.1038/nrd.2017.243 [Google Scholar]
Linares-Fernández S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response. Trends Mol Med. 2020;26(3):311–323. [Google Scholar]
Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396–401. doi:10.1038/nature18300 [Google Scholar]
Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015;217:337–344. doi:10.1016/j.jconrel.2015.08.051 [Google Scholar]
Pardi N, Hogan MJ, Naradikian MS, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215(6):1571–1588. doi:10.1084/jem.20171450 [Google Scholar]
Weissman D. mRNA transcript therapy. Expert Rev Vaccines. 2015;14(2):265–281. doi:10.1586/14760584.2015.973859 [Google Scholar]
Orlandini von Niessen AG, Poleganov MA, Rechner C, et al. Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3’ UTRs Identified by Cellular Library Screening. Mol Ther. 2019;27(4):824–836. doi:10.1016/j.ymthe.2018.12.011 [Google Scholar]
Lima SA, Chipman LB, Nicholson AL, et al. Short poly(A) tails are a conserved feature of highly expressed genes. Nat Struct Mol Biol. 2017;24(12):1057–1063. doi:10.1038/nsmb.3499 [Google Scholar]
Karikó K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39(21):e142. doi:10.1093/nar/gkr695 [Google Scholar]
Baiersdörfer M, Boros G, Muramatsu H, et al. A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA. Mol Ther Nucleic Acids. 2019;15:26–35. doi:10.1016/j.omtn.2019.02.018 [Google Scholar]
Hald Albertsen C, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188:114416. doi:10.1016/j.addr.2022.114416 [Google Scholar]
Patel P, Ibrahim NM, Cheng K. The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA. Trends Pharmacol Sci. 2021;42(6):448–460. doi:10.1016/j.tips.2021.03.002 [Google Scholar]
Dahlman JE, Barnes C, Khan O, et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat Nanotechnol. 2014;9(8):648–655. doi:10.1038/nnano.2014.84 [Google Scholar]
Li Z, Zhang XQ, Ho W, et al. Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines. ACS Nano. 2022;16(11):18936–18950. doi:10.1021/acsnano.2c07822 [Google Scholar]
Liu S, Cheng Q, Wei T, et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat Mater. 2021;20(5):701–710. doi:10.1038/s41563-020-00886-0 [Google Scholar]
Álvarez-Benedicto E, Farbiak L, Márquez Ramírez M, et al. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA). Biomater Sci. 2022;10(2):549–559. Published 2022 Jan 18. doi:10.1039/d1bm01454d [Google Scholar]
Paunovska K, Gil CJ, Lokugamage MP, et al. Analyzing 2000 in Vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery. ACS Nano. 2018;12(8):8341–8349. doi:10.1021/acsnano.8b03640 [Google Scholar]
Patel S, Ashwanikumar N, Robinson E, et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat Commun. 2020;11(1):983. Published 2020 Feb 20. doi:10.1038/s41467-020-14527-2 [Google Scholar]
Patel SK, Billingsley MM, Frazee C, et al. Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells. J Control Release. 2022;347:521–532. doi:10.1016/j.jconrel.2022.05.020 [Google Scholar]
Mui BL, Tam YK, Jayaraman M, et al. Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. Mol Ther Nucleic Acids. 2013;2(12):e139. Published 2013 Dec 17. doi:10.1038/mtna.2013.66 [Google Scholar]
Shi D, Beasock D, Fessler A, et al. To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev. 2022;180:114079. doi:10.1016/j.addr.2021.114079 [Google Scholar]
Simberg D, Barenholz Y, Roffler SR, Landfester K, Kabanov AV, Moghimi SM. PEGylation technology: addressing concerns, moving forward. Drug Deliv. 2025;32(1):2494775. doi:10.1080/10717544.2025.2494775 [Google Scholar]
Cheng Q, Wei T, Jia Y, et al. Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I. Adv Mater. 2018;30(52):e1805308. doi:10.1002/adma.201805308 [Google Scholar]
Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313–320. doi:10.1038/s41565-020-0669-6 [Google Scholar]
Cui Z, Zeng C, Huang F, et al. Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection. Nat Chem Biol. 2022;18(10):1056–1064. doi:10.1038/s41589-022-01094-4 [Google Scholar]
Su K, Shi L, Sheng T, et al. Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nat Commun. 2024;15(1):5659. Published 2024 Jul 5. doi:10.1038/s41467-024-50093-7 [Google Scholar]
Parhiz H, Shuvaev VV, Pardi N, et al. PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake. J Control Release. 2018;291:106–115. doi:10.1016/j.jconrel.2018.10.015 [Google Scholar]
Li Q, Chan C, Peterson N, et al. Engineering Caveolae-Targeted Lipid Nanoparticles To Deliver mRNA to the Lungs. ACS Chem Biol. 2020;15(4):830–836. doi:10.1021/acschembio.0c00003 [Google Scholar]
Herrera-Barrera M, Ryals RC, Gautam M, et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci Adv. 2023;9(2):eadd4623. doi:10.1126/sciadv.add4623 [Google Scholar]
Sinegra AJ, Evangelopoulos M, Park J, Huang Z, Mirkin CA. Lipid Nanoparticle Spherical Nucleic Acids for Intracellular DNA and RNA Delivery. Nano Lett. 2021;21(15):6584–6591. doi:10.1021/acs.nanolett.1c01973 [Google Scholar]
He Q, Gao H, Tan D, Zhang H, Wang JZ. mRNA cancer vaccines: Advances, trends and challenges. Acta Pharm Sin B. 2022;12(7):2969–2989. doi:10.1016/j.apsb.2022.03.011 [Google Scholar]
Lokugamage MP, Vanover D, Beyersdorf J, et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat Biomed Eng. 2021;5(9):1059–1068. doi:10.1038/s41551-021-00786-x [Google Scholar]
Massaro M, Wu S, Baudo G, et al. Lipid nanoparticle-mediated mRNA delivery in lung fibrosis. Eur J Pharm Sci. 2023;183:106370. doi:10.1016/j.ejps.2023.106370 [Google Scholar]
Liu Y, Huang Y, He G, Guo C, Dong J, Wu L. Development of mRNA Lipid Nanoparticles: Targeting and Therapeutic Aspects. Int J Mol Sci. 2024;25(18):10166. Published 2024 Sep 22. doi:10.3390/ijms25181016 [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.